Reported 27 days ago
Novo Nordisk's new weight-loss medication, Amycretin, shows promising results in early trials, achieving a 13.1% weight loss after three months, more than double that of Wegovy's 6%. Unlike Wegovy, Amycretin is a daily pill that works by stimulating the amylin hormone and targeting GLP-1 receptors. Although the findings are preliminary, they indicate strong competition for Eli Lilly in the obesity drug market.
Source: YAHOO